Holen Sie sich die Stockscreener-App
19.34
1.35%
-0.2991
Schlusskurs vom Vortag:
$19.64
Offen:
$19.58
24-Stunden-Volumen:
387.93K
Relative Volume:
0.26
Marktkapitalisierung:
$1.77B
Einnahmen:
$12.59M
Nettoeinkommen (Verlust:
$-212.39M
KGV:
-6.2687
EPS:
-3.0853
Netto-Cashflow:
$-185.92M
1W Leistung:
+13.37%
1M Leistung:
+27.13%
6M Leistung:
+109.01%
1J Leistung:
+33.34%
1-Tages-Spanne:
$19.04
$19.91
1-Wochen-Bereich:
$17.00
$20.46
52-Wochen-Spanne:
$5.1501
$20.46
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Vergleichen Sie IMNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
19.34 | 1.80B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-01 | Eingeleitet | Truist | Buy |
| 2025-09-22 | Eingeleitet | Goldman | Buy |
| 2025-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2025-04-02 | Eingeleitet | Lake Street | Buy |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
Kennedy Capital Management LLC Purchases 94,627 Shares of Immunome, Inc. $IMNM - MarketBeat
Immunome initiated with a Buy at Truist - MSN
Tema Etfs LLC Takes $1.07 Million Position in Immunome, Inc. $IMNM - MarketBeat
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome (NASDAQ:IMNM) Stock Price Up 9.5%Time to Buy? - MarketBeat
Is Immunome Inc a good long term investmentSwing Trading Ideas & Superior Capital Appreciation - earlytimes.in
Immunome (NASDAQ:IMNM) Hits New 1-Year HighShould You Buy? - MarketBeat
Immunome (NASDAQ:IMNM) Trading Down 6.7%Here's Why - MarketBeat
Immunome stock hits 52-week high at 19.16 USD By Investing.com - Investing.com Australia
Immunome stock hits 52-week high at 19.16 USD - Investing.com
It makes sense and dollars to buy Immunome Inc (IMNM) stock - Setenews
Truist Financial Initiates Coverage on Immunome (NASDAQ:IMNM) - MarketBeat
Immunome (NASDAQ:IMNM) Coverage Initiated by Analysts at Truist Financial - Defense World
Immunome (IMNM) Stock Analysis Report | Financials & Insights - Benzinga
Truist Securities initiates coverage on Immunome stock with Buy rating By Investing.com - Investing.com South Africa
IMNM: Truist Securities Initiates Coverage with 'Buy' Rating and - GuruFocus
Truist Securities initiates coverage on Immunome stock with Buy rating - Investing.com India
Truist Initiates Immunome at Buy With $36 Price Target - marketscreener.com
Intech Investment Management LLC Buys 6,141 Shares of Immunome, Inc. $IMNM - Defense World
Geode Capital Management LLC Has $17.31 Million Stock Holdings in Immunome, Inc. $IMNM - MarketBeat
Avoiding Lag: Real-Time Signals in (IMNM) Movement - news.stocktradersdaily.com
How institutional buying supports Immunome Inc. stock2025 Trading Recap & Real-Time Stock Entry Alerts - moha.gov.vn
What drives Immunome Inc stock priceTrading Volume Surges & Smart Trading Plans for Every Investor Type - earlytimes.in
Immunome Inc Stock Analysis and ForecastSell Signals and Alerts & Free Proven Portfolio Growth Strategies - earlytimes.in
Immunome to Present at Upcoming December 2025 Investor Conferences - BioSpace
Immunome (NASDAQ:IMNM) Sets New 12-Month HighHere's Why - MarketBeat
Immunome Inc (IMNM) is looking forward to a strong quarter - Setenews
Immunome to Present at Upcoming Investor Conferences - marketscreener.com
Immunome price target raised to $33 from $25 at Stephens - MSN
Immunome (NASDAQ:IMNM) Upgraded at Wall Street Zen - Defense World
Immunome, Inc.Common Stock (NQ: IMNM - Markets Financial Content
Immunome stock hits 52-week high at $18.79 By Investing.com - Investing.com Nigeria
Immunome stock hits 52-week high at $18.79 - Investing.com
Will Immunome Inc. stock attract more institutional investorsEarnings Overview Summary & Fast Momentum Stock Entry Tips - newser.com
What technical signals suggest for Immunome Inc. stockEarnings Overview Summary & AI Driven Stock Movement Reports - newser.com
How Immunome Inc. stock benefits from tech adoptionTrade Analysis Summary & Short-Term Trading Alerts - newser.com
Will Immunome Inc. stock outperform value stocks2025 Geopolitical Influence & Weekly Top Performers Watchlists - newser.com
Is Immunome Inc. stock a safe haven assetGDP Growth & Weekly Top Gainers Trade List - newser.com
Is Immunome Inc. stock bottoming out2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
Immunome (NASDAQ:IMNM) Stock Price Expected to Rise, Stephens Analyst Says - Defense World
Lake Street Sticks to Their Buy Rating for Immunome (IMNM) - The Globe and Mail
Can swing trading help recover from Immunome Inc. lossesJuly 2025 Action & Daily Volume Surge Signals - newser.com
Immunome announces $125 million stock offering - MSN
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunome Inc-Aktie (IMNM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):